

# **Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030**

<https://marketpublishers.com/r/G560D23BF894EN.html>

Date: September 2020

Pages: 529

Price: US\$ 7,000.00 (Single User License)

ID: G560D23BF894EN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

Market Report Coverage - Precision Medicine

Market Segmentation

By Ecosystem: Applied Sciences, Precision Diagnostics, Precision Therapeutics, Digital Health and IT

By Application: Cancer, Infectious Disease, Neurology, Cardiovascular, Endocrinology, Gastroenterology and Other Applications

By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Cross Segmentation

Applied Sciences: By Product, By Technology, By End User, By Region

Precision Diagnostics: By Product, By Technology, By End User, By Region

Precision Therapeutics: By Product, By Technology, By End User, By Region

## Digital Health and IT: By Product, By Technology, By End User, By Region

### Regional Segmentation

North America: U.S. and Canada

Europe: Germany, France, U.K., Italy, Spain, and Rest-of-Europe

Asia-Pacific: Japan, China, India, Australia, and Rest-of-Asia-Pacific

Latin America: Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

### Growth Drivers

Advancement of Sequencing Technologies

Rising Prevalence of Chronic Diseases

Growing Demand for Preventive Care

Shifting the Significance in Medicine from Reaction to Prevention

Reducing Adverse Drug Reactions Through Pharmacogenomics Test

Potential to Reduce the Overall Healthcare Cost Across the Globe

### Market Challenges

Unified Framework for Data Integration

Limited Knowledge about Molecular Mechanism/ Interaction

Lack of Robust Reimbursement Landscape

## Regulatory Hurdles

## Market Opportunities

Targeted Gene Therapy

Expansion into the Emerging Markets

Collaborations and Partnerships Across Value Chain to Accelerate the Market Entry

## Key Companies Profiled

Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc., Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMérieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America, MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi S.A., Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific, Inc.

## Key Questions Answered in this Report:

What are the estimated and projected numbers for the global precision medicine market for 2020 and 2030?

What are the drivers, challenges, and opportunities that are influencing the dynamics of the market?

What is the competition layout of the market?

What are the parameters on which competition mapping is carried out in the

study?

Which key development strategies are being followed and implemented by major players to help them sustain in the market?

How are different segments of the market expected to perform during the forecast period from 2020 to 2030? The segments included in the comprehensive market study are:

product type

region

technology

application

Which leading players are currently dominating the market and what is the expected future scenario?

Which companies are anticipated to be highly disruptive in the future, and why?

How can the changing dynamics of the market impact the market share of different players operating in the market?

What are the strategic recommendations offered in the study?

## Market Overview

Precision medicine refers to the medicine developed as per an individual's genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule. In the precision medicine market, the application of molecular biology is to study the cause of a patient's disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems. This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into

healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

The current precision medicine market is mainly dominated by several majors, such as Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc, Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMérieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc. Intomics A/S, and Johnson & Johnson Company, Konica Minolta, Inc.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

### Competitive Landscape

Major players, such as Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc, Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMérieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG., Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc., Randox Laboratories Ltd., Sanofi SA, Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific, Inc. including among others, led the number of key developments witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe.

## Contents

### 1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

### 2 RESEARCH SCOPE

2.1 Scope of Study

2.2 Key Questions Answered in the Report

2.3 Global Precision Medicine Market: Research Methodology

2.4 Criteria for Company Profiling

### 3 RESEARCH METHODOLOGY

3.1 Primary Data Sources

3.2 Secondary Data Sources

3.3 Market Estimation Model

### 4 GLOBAL PRECISION MEDICINE MARKET OVERVIEW

4.1 Market Definition

4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine

4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

4.4 Initiatives and Programs

4.5 Precision Medicine: Enabling Technologies and Applications

4.5.1 Innovators

4.5.1.1 3D DNA Printing

4.5.1.1.1 Introduction

4.5.1.1.2 Role of 3D DNA Printing

4.5.1.2 RNA-Seq

4.5.1.2.1 Introduction

4.5.1.2.2 Role of RNA-Seq in Precision Medicine

4.5.1.2.3 Key Players

4.5.1.3 4D Molecular Imaging

4.5.1.3.1 Introduction

4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine

4.5.1.3.3 Key Players

## 4.5.2 Early Adopters

### 4.5.2.1 CRISPR

#### 4.5.2.1.1 Introduction

#### 4.5.2.1.2 Role of CRISPR in Precision Medicine

#### 4.5.2.1.3 Key Players

### 4.5.2.2 Blockchain

#### 4.5.2.2.1 Introduction

#### 4.5.2.2.2 Role of Blockchain in Precision Medicine

#### 4.5.2.2.3 Key Players

### 4.5.2.3 Imaging Informatics

#### 4.5.2.3.1 Introduction

#### 4.5.2.3.2 Role of Imaging Informatics in Precision Medicine

#### 4.5.2.3.3 Key Players

## 4.5.3 Early Majority

### 4.5.3.1 Artificial Intelligence (AI)

#### 4.5.3.1.1 Introduction

#### 4.5.3.1.2 Role of Artificial Intelligence in Precision Medicine

#### 4.5.3.1.3 Key Players

### 4.5.3.2 Circulating Free DNA (cfDNA)

#### 4.5.3.2.1 Introduction

#### 4.5.3.2.2 Role of cfDNA in Precision Medicine

#### 4.5.3.2.3 Key Players

### 4.5.3.3 Big Data

#### 4.5.3.3.1 Introduction

#### 4.5.3.3.2 Role of Big Data in Precision Medicine

#### 4.5.3.3.3 Key Players

### 4.5.3.4 Next-Generation Sequencing (NGS)

#### 4.5.3.4.1 Introduction

#### 4.5.3.4.2 Role of NGS in Precision Medicine

#### 4.5.3.4.3 Key Players

### 4.5.3.5 Health Informatics

#### 4.5.3.5.1 Introduction

#### 4.5.3.5.2 Role of Health Informatics in Precision Medicine

#### 4.5.3.5.3 Key players

### 4.5.3.6 Bioinformatics

#### 4.5.3.6.1 Introduction

#### 4.5.3.6.2 Role of Bioinformatics in Precision Medicine

#### 4.5.3.6.3 Key Players

## 4.5.4 Late Majority

- 4.5.4.1 Polymerase Chain Reactions (PCR)
  - 4.5.4.1.1 Introduction
  - 4.5.4.1.2 Role of PCR in Precision Medicine
  - 4.5.4.1.3 Key players
- 4.5.4.2 Microarray
  - 4.5.4.2.1 Role of Microarray in Precision Medicine
  - 4.5.4.2.2 Key Players
- 4.6 COVID-19 Impact on the Global Precision Medicine Market

## **5 MARKET DYNAMICS**

- 5.1 Overview
- 5.2 Market Drivers
  - 5.2.1 Advancement of Sequencing Technologies
  - 5.2.2 Rising Prevalence of Chronic Diseases
  - 5.2.3 Growing Demand for Preventive Care
  - 5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention
  - 5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test
  - 5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe
- 5.3 Market Restraints
  - 5.3.1 Unified Framework for Data Integration
  - 5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction
  - 5.3.3 Lack of Robust Reimbursement Landscape
  - 5.3.4 Regulatory Hurdles
- 5.4 Market Opportunities
  - 5.4.1 Targeted Gene Therapy
  - 5.4.2 Expansion into the Emerging Markets
  - 5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

## **6 INDUSTRY INSIGHTS**

- 6.1 Patent Analysis
- 6.2 Legal Requirements and Regulations
- 6.3 Pipeline Analysis
- 6.4 Legal Requirements and Framework by the FDA
- 6.5 Legal Requirements and Framework by the EMA
- 6.6 Legal Requirements and Framework by the MHLW



## **7 COMPETITIVE LANDSCAPE**

### 7.1 Synergistic Activities

7.1.1 Product launches, Enhancements, and Upgradation

7.1.2 Product Approvals

7.1.3 Mergers and Acquisitions

7.1.4 Business Expansion

### 7.2 Market Share Analysis

7.2.1 Market Share Analysis by Applied Sciences, 2019

7.2.2 Market Share Analysis by Precision Diagnostics, 2019

7.2.3 Market Share Analysis by Precision Therapeutics, 2019

7.2.4 Market Share Analysis by Digital Health and IT, 2019

## **8 GLOBAL PRECISION MEDICINE MARKET (BY ECOSYSTEM)**

### 8.1 Overview

### 8.2 Applied Sciences

#### 8.2.1 Genomics

#### 8.2.2 Global Precision Medicine Genomics Market (by Technology)

##### 8.2.2.1 Polymerase Chain Reaction (PCR)

8.2.2.1.1 Global Precision Medicine PCR Market (by Product)

8.2.2.1.2 Global Precision Medicine PCR Market (by End User)

8.2.2.1.3 Global Precision Medicine PCR Market (by Region)

##### 8.2.2.2 Next-Generation Sequencing (NGS)

8.2.2.2.1 Global Precision Medicine NGS Market (by Product)

8.2.2.2.2 Global Precision Medicine NGS Market (by Technology)

8.2.2.2.3 Global Precision Medicine NGS Market (by End User)

8.2.2.2.4 Global Precision Medicine NGS Market (by Region)

##### 8.2.2.3 Genome Editing

8.2.2.3.1 Global Precision Medicine Genome Editing Market (by Product)

8.2.2.3.2 Global Precision Medicine Genome Editing Market (by End User)

8.2.2.3.3 Global Precision Medicine Genome Editing Market (by Region)

##### 8.2.2.4 Other Technologies

8.2.2.4.1 Global Precision Medicine Other Technologies Market (by Region)

#### 8.2.3 Pharmacogenomics

8.2.3.1 Global Precision Medicine Pharmacogenomics Market (by  
Pharmacogenomics Services)

8.2.3.2 Global Precision Medicine Pharmacogenomics Market (by End User)

8.2.3.3 Global Precision Medicine Pharmacogenomics Market (by Region)

- 8.2.4 Other Applied Sciences
- 8.3 Precision Diagnostics
  - 8.3.1 Molecular Diagnostics (MDx)
  - 8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type)
    - 8.3.2.1 Non-Invasive Prenatal Testing (NIPT)
      - 8.3.2.1.1 Global Precision Medicine NIPT Market (by Platform)
      - 8.3.2.1.2 Global Precision Medicine NIPT Market (by Region)
    - 8.3.2.2 Companion Diagnostics
      - 8.3.2.2.1 Global Precision Medicine Companion Diagnostics Market (by Technology)
      - 8.3.2.2.2 Global Precision Medicine Companion Diagnostics Market (by Indication)
      - 8.3.2.2.3 Global Precision Medicine Companion Diagnostics Market (by Region)
    - 8.3.2.3 Liquid Biopsy
      - 8.3.2.3.1 Global Precision Medicine Liquid Biopsy Market (by Indication)
      - 8.3.2.3.2 Global Precision Medicine Liquid Biopsy Market (by Region)
    - 8.3.2.4 Other Molecular Diagnostics
      - 8.3.2.4.1 Global Precision Medicine Other Molecular Diagnostics Market (by Type)
      - 8.3.2.4.2 Global Precision Medicine Other Molecular Diagnostics Market (by Region)
  - 8.3.3 Medical Imaging
    - 8.3.3.1 Global Precision Medicine Medical Imaging Market (by Type)
      - 8.3.3.1.1 Imaging Analytics
      - 8.3.3.1.2 Imaging Computer-Aided Detection (CADx)
    - 8.3.3.2 Global Precision Medicine Medical Imaging Market (by Region)
- 8.4 Digital Health and Information Technology
  - 8.4.1 Global Precision Medicine Digital Health and Information Technology Market (by Type)
    - 8.4.1.1 Clinical Decision Support Systems (CDSS)
    - 8.4.1.2 Big Data Analytics
    - 8.4.1.3 IT Infrastructure
      - 8.4.1.3.1 Global Precision Medicine IT Infrastructure Market (by Type)
    - 8.4.1.4 Genomics Informatics
      - 8.4.1.4.1 Global Precision Medicine Genomics Informatics Market (by Product Type)
    - 8.4.1.5 In-Silico Informatics
    - 8.4.1.6 Mobile Health
  - 8.4.2 Global Precision Medicine Digital Health and Information Technology Market (by End User)
  - 8.4.3 Global Precision Medicine Digital Health and Information Technology Market, (by Region)

## 8.5 Precision Therapeutics

### 8.5.1 Global Precision Medicine Therapeutics Market (by Type)

#### 8.5.1.1 Clinical Trials

##### 8.5.1.1.1 Global Precision Medicine Clinical Trials Market (by Region)

#### 8.5.1.2 Cell Therapy

##### 8.5.1.2.1 Global Precision Medicine Cell Therapy Market (by Region)

#### 8.5.1.3 Drug Discovery and Research

##### 8.5.1.3.1 Global Precision Medicine Drug Discovery and Research Market (by Region),

#### 8.5.1.4 Gene Therapy

##### 8.5.1.4.1 Global Precision Medicine Drug Discovery and Research Market (by Region)

## **9 GLOBAL PRECISION MEDICINE MARKET (BY APPLICATION)**

### 9.1 Overview

### 9.2 Oncology

#### 9.2.1 Cancer Precision Medicine Drugs and Indications

### 9.3 Infectious Diseases

#### 9.3.1 Infectious Diseases Precision Medicine Drugs and Indications

### 9.4 Neurology

#### 9.4.1 Neurology Precision Medicine Drugs and Indications

### 9.5 Cardiovascular

#### 9.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications

### 9.6 Lifestyle and Endocrinology

#### 9.6.1 Endocrinology Precision Medicine Drugs and Indications

### 9.7 Gastroenterology

#### 9.7.1 Gastroenterology Precision Medicine Drugs and Indications

### 9.8 Other Applications

#### 9.8.1 Precision Drugs for Other Applications

## **10 GLOBAL PRECISION MEDICINE MARKET, (BY REGION)**

### 10.1 Overview

### 10.2 North America

#### 10.2.1 North America Precision Medicine Market (by Ecosystem)

#### 10.2.2 U.S.

##### 10.2.2.1 Overview of Precision Medicine

##### 10.2.2.2 Key Trends

- 10.2.2.3 Promoting Factors
- 10.2.2.4 Recent Key Developments
- 10.2.2.5 Funding Scenario/Investments
- 10.2.2.6 Regulatory Scenario
- 10.2.2.7 Key Players
- 10.2.3 Canada
  - 10.2.3.1 Overview of Precision Medicine
  - 10.2.3.2 Key Trends
  - 10.2.3.3 Promoting Factors
  - 10.2.3.4 Recent Key Developments
  - 10.2.3.5 Regulatory Scenario
  - 10.2.3.6 Key Players
- 10.3 Europe
  - 10.3.1 Europe Precision Medicine Market (by Ecosystem)
  - 10.3.2 Germany
    - 10.3.2.1 Overview of Precision Medicine
    - 10.3.2.2 Key Trends
    - 10.3.2.3 Promoting Factors
    - 10.3.2.4 Recent Key Developments
    - 10.3.2.5 Key Players
  - 10.3.3 France
    - 10.3.3.1 Overview of Precision Medicine
    - 10.3.3.2 Key Trends
    - 10.3.3.3 Promoting Factors
    - 10.3.3.4 Recent Key Developments
    - 10.3.3.5 Key Players
  - 10.3.4 Italy
    - 10.3.4.1 Overview of Precision Medicine
    - 10.3.4.2 Key Trends
    - 10.3.4.3 Promoting Factors
    - 10.3.4.4 Recent Key Developments
    - 10.3.4.5 Funding Scenario/Investments
  - 10.3.5 U.K.
    - 10.3.5.1 Overview of Precision Medicine
    - 10.3.5.2 Key Trends
    - 10.3.5.3 Promoting Factors
    - 10.3.5.4 Recent Key Developments
    - 10.3.5.5 Funding Scenario/Investments
    - 10.3.5.6 Key Players

- 10.3.6 Spain
  - 10.3.6.1 Overview of Precision Medicine
  - 10.3.6.2 Key Trends
  - 10.3.6.3 Promoting Factors
  - 10.3.6.4 Recent Key Developments
  - 10.3.6.5 Key Players
- 10.3.7 Rest-of-Europe
  - 10.3.7.1 Switzerland
- 10.4 Asia-Pacific
  - 10.4.1 Asia-Pacific Precision Medicine Market (by Ecosystem)
  - 10.4.2 China
    - 10.4.2.1 Overview of Precision Medicine
    - 10.4.2.2 Key Trends
    - 10.4.2.3 Promoting Factors
    - 10.4.2.4 Recent Key Developments
    - 10.4.2.5 Key Players
  - 10.4.3 Japan
    - 10.4.3.1 Overview of Precision Medicine
    - 10.4.3.2 Key Trends
    - 10.4.3.3 Promoting Factors
    - 10.4.3.4 Recent Key Developments
    - 10.4.3.5 Reimbursement Scenario
    - 10.4.3.6 Key Players
  - 10.4.4 Australia
    - 10.4.4.1 Overview of Precision Medicine
    - 10.4.4.2 Key Trends
    - 10.4.4.3 Promoting Factors
    - 10.4.4.4 Recent Key Developments
    - 10.4.4.5 Regulatory Scenario
    - 10.4.4.6 Key Players
  - 10.4.5 India
    - 10.4.5.1 Overview of Precision Medicine
    - 10.4.5.2 Key Trends
    - 10.4.5.3 Promoting Factors
    - 10.4.5.4 Recent Key Developments
    - 10.4.5.5 Key Players
  - 10.4.6 Rest-of-Asia-Pacific (RoAPAC)
    - 10.4.6.1 Singapore
      - 10.4.6.1.1 Regulatory Framework

10.4.6.2 South Korea

10.4.6.3 Vietnam

10.5 Latin America

10.5.1 Latin America Precision Medicine Market (by Ecosystem)

10.5.2 Brazil

10.5.2.1 Overview of Precision Medicine

10.5.3 Mexico

10.5.3.1 Overview of Precision Medicine

10.5.3.2 Recent Key Developments

10.5.4 Rest-of-Latin America (RoLA)

10.6 Rest-of-the-World (RoW)

10.6.1 Rest-of-the-World Precision Medicine Market (by Ecosystem)

10.6.1.1 Israel

10.6.1.2 Saudi Arabia

10.6.1.3 United Arab Emirates

10.6.1.4 South Africa

10.6.1.5 Russia

## **11 COMPANY PROFILES**

11.1 Overview

11.2 Abbott Laboratories

11.2.1 Company Overview

11.2.2 Role of Abbott Laboratories in Global Precision Medicine Market

11.2.3 Financials

11.2.4 Key Insights About Financial Health of the Company

11.2.5 SWOT Analysis

11.3 Almac Group Ltd.

11.3.1 Company Overview

11.3.2 Role of Almac Group Ltd. in Global Precision Medicine Market

11.3.3 SWOT Analysis

11.4 Amgen Inc.

11.4.1 Company Overview

11.4.2 Role of Amgen Inc. in Global Precision Medicine Market

11.4.3 Financials

11.4.4 Key Insights about Financial Health of the Company

11.4.5 SWOT Analysis

11.5 ANGLE plc

11.5.1 Company Overview

- 11.5.2 Role of ANGLE plc in Global Precision Medicine Market
- 11.5.3 Financials
- 11.5.4 Key Insights about Financial Health of the Company
- 11.5.5 SWOT Analysis
- 11.6 Astellas Pharma Inc.
  - 11.6.1 Company Overview
  - 11.6.2 Role of Astellas Pharma Inc.in Global Precision Medicine Market
  - 11.6.3 Financials
  - 11.6.4 Key Insights about Financial Health of the Company
  - 11.6.5 SWOT Analysis
- 11.7 Astra Zeneca
  - 11.7.1 Company Overview
  - 11.7.2 Role of Astra Zeneca in Global Precision Medicine Market
  - 11.7.3 Financials
  - 11.7.4 SWOT Analysis
- 11.8 ASURAGEN INC.
  - 11.8.1 Company Overview
  - 11.8.2 Role of ASURAGEN Inc. in Global Precision Medicine Market
  - 11.8.3 SWOT Analysis
- 11.9 Bio-Rad Laboratories, Inc.
  - 11.9.1 Company Overview
  - 11.9.2 Role of Bio-Rad Laboratories, Inc. in Global Precision Medicine Market
  - 11.9.3 Financials
  - 11.9.4 SWOT Analysis
- 11.10 bioMérieux S.A.
  - 11.10.1 Company Overview
  - 11.10.2 Role of bioMérieux SA. in Global Precision Medicine Market
  - 11.10.3 Financials
  - 11.10.4 SWOT Analysis
- 11.11 Bristol-Myers Squibb Company
  - 11.11.1 Company Overview
  - 11.11.2 Role of Bristol-Myers Squibb Company in Global Precision Medicine Market
  - 11.11.3 Financials
  - 11.11.4 Key Insights about Financial Health of the Company
  - 11.11.5 SWOT Analysis
- 11.12 Cardiff Oncology
  - 11.12.1 Company Overview
  - 11.12.2 Role of Cardiff Oncology in Global Precision Medicine Market
  - 11.12.3 Financials

- 11.12.4 Key Insights About Financial Health of the Company
- 11.12.5 SWOT Analysis
- 11.13 CETICS Healthcare Technologies GmbH
  - 11.13.1 Company Overview
  - 11.13.2 Role CETICS Healthcare Technologies GmbH in Global Precision Medicine Market
  - 11.13.3 SWOT Analysis
- 11.14 Danaher Corporation
  - 11.14.1 Company Overview
  - 11.14.2 Role of Danaher Corporation in Global Precision Medicine Market
  - 11.14.3 Financials
  - 11.14.4 SWOT Analysis
- 11.15 Eli Lilly and Company Limited
  - 11.15.1 Company Overview
  - 11.15.2 Role of Eli Lilly and Company Limited in Global Precision Medicine Market
  - 11.15.3 Financials
  - 11.15.4 SWOT Analysis
- 11.16 Epic Sciences, Inc.
  - 11.16.1 Company Overview
  - 11.16.2 Role Epic Sciences, Inc. in Global Precision Medicine Market
  - 11.16.3 SWOT Analysis
- 11.17 F. Hoffmann-La Roche Ltd
  - 11.17.1 Company Overview
  - 11.17.2 Role of F. Hoffman-LA Roche Ltd in Global Precision Medicine Market
  - 11.17.3 Financials
  - 11.17.4 Key Insights About Financial Health of the Company
  - 11.17.5 SWOT Analysis
- 11.18 General Electric Company
  - 11.18.1 Company Overview
  - 11.18.2 Role of GE Corporation in Global Precision Medicine Market
  - 11.18.3 Financials
  - 11.18.4 Key Insights about Financial Health of the Company
  - 11.18.5 SWOT Analysis
- 11.19 Gilead Sciences, Inc.
  - 11.19.1 Company Overview
  - 11.19.2 Role of Gilead Sciences, Inc. in Global Precision Medicine Market
  - 11.19.3 SWOT Analysis
- 11.20 GlaxoSmithKline plc
  - 11.20.1 Company Overview



- 11.20.2 Role of GlaxoSmithKline Plc in Global Precision Medicine Market
- 11.20.3 Financials
- 11.20.4 Key Insights about Financial Health of the Company
- 11.20.5 SWOT Analysis
- 11.21 Illumina, Inc.
  - 11.21.1 Company Overview
  - 11.21.2 Role of Illumina, Inc. in Global Precision Medicine Market
  - 11.21.3 Financials
  - 11.21.4 Key Insights About Financial Health of the Company
  - 11.21.5 SWOT Analysis
- 11.22 Intomics A/S
  - 11.22.1 Company Overview
  - 11.22.2 Role Intomics A/S in Global Precision Medicine Market
  - 11.22.3 SWOT Analysis
- 11.23 Johnson & Johnson Services, Inc.
  - 11.23.1 Company Overview
  - 11.23.2 Role of Johnson and Johnson in Global Precision Medicine Market
  - 11.23.3 Financials
  - 11.23.4 Key Insights about Financial Health of the Company
  - 11.23.5 SWOT Analysis
- 11.24 Konica Minolta, Inc.
  - 11.24.1 Company Overview
  - 11.24.2 Role of Konica Minolta, Inc. in Global Precision Medicine Market
  - 11.24.3 Financials
  - 11.24.4 SWOT Analysis
- 11.25 Laboratory Corporation of America Holdings
  - 11.25.1 Company Overview
  - 11.25.2 Role of Laboratory Corporation of America Holdings in Global Precision Medicine Market
  - 11.25.3 Financials
  - 11.25.4 SWOT Analysis
- 11.26 MDx Health, Inc.
  - 11.26.1 Company Overview
  - 11.26.2 Role of MDx Health, Inc. in Global Precision Medicine Market
  - 11.26.3 Financials
  - 11.26.4 SWOT Analysis
- 11.27 Menarini Silicon Biosystems, Inc.
  - 11.27.1 Company Overview
  - 11.27.2 Role Menarini Silicon Biosystems, Inc. in Global Precision Medicine Market

- 11.27.3 SWOT Analysis
- 11.28 Merck KGaA
  - 11.28.1 Company Overview
  - 11.28.2 Role of Merck KGaA in Global Precision Medicine Market
  - 11.28.3 Financials
  - 11.28.4 Key Insights About Financial Health of the Company
  - 11.28.5 SWOT Analysis
- 11.29 Myriad Genetics, Inc.
  - 11.29.1 Company Overview
  - 11.29.2 Role of Myriad Genetics, Inc. in Global Precision Medicine Market
  - 11.29.3 Financials
  - 11.29.4 Key Insights About Financial Health of the Company
  - 11.29.5 SWOT Analysis
- 11.30 Novartis AG
  - 11.30.1 Company overview
  - 11.30.2 Role of Novartis AG in Global Precision Medicine Market
  - 11.30.3 Financials
  - 11.30.4 Key Insights about Financial Health of the Company
  - 11.30.5 SWOT Analysis
- 11.31 Oracle Corporation.
  - 11.31.1 Company Overview
  - 11.31.2 Role of Oracle Corporation in Global Precision Medicine Market
  - 11.31.3 Financials
  - 11.31.4 Key Insights about Financial Health of the Company
  - 11.31.5 SWOT Analysis
- 11.32 Pacific Biosciences of California, Inc.
  - 11.32.1 Company Overview
  - 11.32.2 Role of Pacific Biosciences of California, Inc. in Global Precision Medicine Market
  - 11.32.3 Financials
  - 11.32.4 Key Insights About Financial Health of the Company
  - 11.32.5 SWOT Analysis
- 11.33 Partek, Inc.
  - 11.33.1 Company Overview
  - 11.33.2 Role Partek, Inc. in Global Precision Medicine Market
  - 11.33.3 SWOT Analysis
- 11.34 Pfizer Inc.
  - 11.34.1 Company Overview
  - 11.34.2 Role of Pfizer, Inc. in Global Precision Medicine Market

- 11.34.3 Financials
- 11.34.4 Key Insights about Financial Health of the Company
- 11.34.5 SWOT Analysis
- 11.35 QIAGEN N.V.\*
  - 11.35.1 Company Overview
  - 11.35.2 Role of QIAGEN N.V. in Global Precision Medicine Market
  - 11.35.3 Financials
  - 11.35.4 Key Insights About Financial Health of the Company
  - 11.35.5 SWOT Analysis
- 11.36 Quest Diagnostics Incorporated
  - 11.36.1 Company Overview
  - 11.36.2 Role of Quest Diagnostics Incorporated in Global Precision Medicine Market
  - 11.36.3 Financials
  - 11.36.4 SWOT Analysis
- 11.37 Randox Laboratories Ltd.
  - 11.37.1 Company Overview
  - 11.37.2 Role of Randox Laboratories Ltd. in Global Precision Medicine Market
  - 11.37.3 SWOT Analysis
- 11.38 Sanofi S.A.
  - 11.38.1 Company Overview
  - 11.38.2 Role of Sanofi SA in Global Precision Medicine Market
  - 11.38.3 Financials
  - 11.38.4 Key Insights about Financial Health of the Company
  - 11.38.5 SWOT Analysis
- 11.39 Sysmex Corporation
  - 11.39.1 Company Overview
  - 11.39.2 Role of Sysmex Corporation in Global Precision Medicine Market
  - 11.39.3 Financials
  - 11.39.4 Key Insights about Financial Health of the Company
  - 11.39.5 SWOT Analysis
- 11.40 Teva Pharmaceuticals Industries Ltd.
  - 11.40.1 Company Overview
  - 11.40.2 Role of Teva Pharmaceuticals Industries Ltd. in Global Precision Medicine Market
  - 11.40.3 Financials
  - 11.40.4 Key Insights about Financial Health of the Company
  - 11.40.5 SWOT Analysis
- 11.41 Thermo Fisher Scientific Inc.
  - 11.41.1 Company Overview

11.41.2 Role of Thermo Fisher Scientific Inc. in Global Precision Medicine Market

11.41.3 Financials

11.41.4 Key Insights About Financial Health of the Company

11.41.5 SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 4.1: Initiatives and Programs

Table 5.1: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030)

Table 5.2: Estimated Number of Cancer Incident Cases for 2018 and 2040

Table 5.3: Policy and Guidance Documents from the U.S. FDA

Table 6.1: Pipeline Analysis (by Company)

Table 6.2: Pipeline Analysis (by Product)

Table 6.3: Precision Medicine Drugs Pipeline Analysis

Table 8.1: 12. List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labeling

Table 8.2: Key Approved Therapeutics with FDA-Mandated Companion Diagnostics Tests

Table 8.3: 12. List of FDA Approved Companion Diagnostics

Table 8.4: Commercially Available Primary and Secondary Analysis Tools Providers

Table 9.1: Cancer Precision Medicine Drugs and Indications

Table 9.2: Infectious Diseases Precision Medicine Drugs and Indications

Table 9.3: Neurology Precision Medicine Drugs and Indications

Table 9.4: Cardiovascular Precision Medicine Drugs/Tests/ and Indications

Table 9.5: Endocrinology Precision Medicine Drugs and Indications

Table 9.6: Gastroenterology Precision Medicine Drugs and Indications

Table 9.7: Precision Drugs for Other Applications

Table 10.1: Funding scenario in Universities

## List Of Figures

### LIST OF FIGURES

Figure 1: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure

Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care

Figure 3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)

Figure 4: Impact Analysis of Market Drivers and Market Challenges on the Global Precision Medicine Market

Figure 5: Global Precision Medicine Market (by Ecosystem), 2019 vs. 2030 (\$Billion)

Figure 6: Global Precision Medicine Market (by Application Area), 2019 vs. 2030 (\$Billion)

Figure 7: Global Precision Medicine Market (by Region) Snapshot

Figure 1.1: Global Precision Medicine Market Segmentation

Figure 1.2: Global Precision Medicine Market Methodology

Figure 3.1: Primary Research Methodology

Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)

Figure 4.1: Precision Medicine Approach

Figure 4.2: Evolution of Precision Medicine Technology

Figure 4.3: Precision Medicine: Enabling Technologies and Applications

Figure 4.4: Structured Big Data Reporting Benefits

Figure 4.5: Generalized Process for the Microarray

Figure 4.6: Global Precision Medicine Market: COVID-19 Impact

Figure 5.1: Impact Analysis

Figure 5.2: Percent of Patients Whose Tumor Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs

Figure 6.1: Patent Analysis

Figure 6.2: Role of FDA in Advancing Precision Medicine

Figure 6.3: FDA Guidelines for CDx Approval

Figure 7.1: Share of Key Developments and Strategies, January 2012–July 2020

Figure 7.2: Synergistic Activities (January 2012- July 2020)

Figure 7.3: Product launches, Enhancements, and Upgradation by Companies (January 2012-July 2020)

Figure 7.4: Product Approvals by Companies (January 2012-July 2020)

Figure 7.5: Merger and Acquisitions Share by Companies (January 2012-July 2020)

Figure 7.6: Business Expansion Share by Companies (January 2012-July 2020)

Figure 7.7: Market Share Analysis for PM Applied Sciences Ecosystem, 2019

Figure 7.8: Market Share Analysis for PM Diagnostics Ecosystem, 2019

- Figure 7.9: Market Share Analysis by PM Therapeutics Ecosystem, 2019
- Figure 7.10: Market Share Analysis by PM Digital Health and IT Ecosystem, 2019
- Figure 7.11: Share of Key Developments and Strategies, January 2014–February 2020
- Figure 8.1: Precision Medicine: The Ecosystem
- Figure 8.2: Global Precision Medicine Market (by Ecosystem)
- Figure 8.3: Global Precision Medicine Market (by Ecosystem), 2019-2030
- Figure 8.4: Global Precision Medicine Market (by Applied Sciences)
- Figure 8.5: Global Precision Medicine Market (by Applied Sciences), 2019-2030
- Figure 8.6: Precision Medicine: Multi-omics Sciences
- Figure 8.7: Global Precision Medicine Applied Sciences Market (by Type), 2019-2030
- Figure 8.8: Precision Medicine: Genomics
- Figure 8.9: Global Precision Medicine Genomics Market, 2019-2030
- Figure 8.10: Global Precision Medicine Genomics Market (by Technology), 2019-2030
- Figure 8.11: Global Precision Medicine PCR Market, 2019-2030
- Figure 8.12: Global Precision Medicine PCR Market (by Product ), 2019-2030
- Figure 8.13: Global Precision Medicine PCR Market (by End User), 2019-2030
- Figure 8.14: Global Precision Medicine PCR Market (by Region), 2019-2030
- Figure 8.15: Evolution of Next-Generation Sequencing
- Figure 8.16: Global Precision Medicine NGS Market, 2019-2030
- Figure 8.17: Global Precision Medicine NGS Market (by Product), 2019-2030
- Figure 8.18: Global Precision Medicine NGS Market (by Technology), 2019-2030
- Figure 8.19: Global Precision Medicine NGS Market (by End User), 2019-2030
- Figure 8.20: Global Precision Medicine NGS Market (by Region), 2019-2030
- Figure 8.21: Global Precision Medicine Genome Editing Market, 2019-2030
- Figure 8.22: Global Precision Medicine Genome Editing Market (by Product), 2019-2030
- Figure 8.23: Global Precision Medicine Genome Editing Market (by End User), 2019-2030
- Figure 8.24: Global Precision Medicine Genome Editing Market (by Region), 2019-2030
- Figure 8.25: Global Precision Medicine Other Technologies Market, 2019-2030
- Figure 8.26: Global Precision Medicine Other Technologies Market (by Region), 2019-2030
- Figure 8.27: Role of Biomarkers in Pharmacogenomics
- Figure 8.28: Role of FDA In Pharmacogenomics
- Figure 8.29: Global Precision Medicine Pharmacogenomics Market, 2019-2030
- Figure 8.30: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2019-2030
- Figure 8.31: Global Precision Medicine Pharmacogenomics Market (by End User), 2019-2030

Figure 8.32: Global Precision Medicine Pharmacogenomics Market (by Region), 2019-2030

Figure 8.33: Global Precision Medicine Other Applied Sciences Market, 2019-2030

Figure 8.34: Precision Medicine: Diagnostics

Figure 8.35: Global Precision Medicine Market (by Precision Diagnostics)

Figure 8.36: Global Precision Medicine Market (by Precision Diagnostics), 2019-2030

Figure 8.37: Global Precision Medicine Diagnostics Market (by Type), 2019-2030

Figure 8.38: General Workflow of a Molecular Diagnostic Assay

Figure 8.39: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)

Figure 8.40: Global Precision Medicine Molecular Diagnostics Market, 2019-2030

Figure 8.41: Global Precision Medicine Molecular Diagnostics Market (by Type), 2019-2030

Figure 8.42: Benefits and Risks Associated with NIPT

Figure 8.43: Global Precision Medicine NIPT Market, 2019-2030

Figure 8.44: Global Precision Medicine NIPT Market (by Platform), 2019-2030

Figure 8.45: Global Precision Medicine NIPT Market (by Region), 2019-2030

Figure 8.46: Drug and Companion Diagnostics Development Process

Figure 8.47: Benefits and Risks Associated with Companion Diagnostics

Figure 8.48: Global Precision Medicine Companion Diagnostics Market, 2019-2030

Figure 8.49: Global Precision Medicine Companion Diagnostics Market (by Technology), 2019-2030

Figure 8.50: Global Precision Medicine Companion Diagnostics Market (by Indication), 2019-2030

Figure 8.51: Global Precision Medicine Companion Diagnostics Market (by Region), 2019-2030

Figure 8.52: Clinical Applications of Liquid Biopsy

Figure 8.53: Global Precision Medicine Liquid Biopsy Market, 2019-2030

Figure 8.54: Global Precision Medicine Liquid Biopsy Market (by Indication), 2019-2030

Figure 8.55: Global Precision Medicine Liquid Biopsy Market (by Region), 2019-2030

Figure 8.56: Global Precision Medicine Other Molecular Diagnostics Market, 2020-2030

Figure 8.57: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2019-2030

Figure 8.58: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2019-2030

Figure 8.59: Global Precision Medicine Medical Imaging Market, 2019-2030

Figure 8.60: Global Precision Medicine Medical Imaging Market (by Type), 2019-2030

Figure 8.61: Global Precision Medicine Imaging Analytics Market, 2019-2030

Figure 8.62: Global Precision Medicine CADx Market, 2019-2030

Figure 8.63: Global Precision Medicine Medical Imaging Market (by Region), 2019-2030



Figure 8.64: Global Precision Medicine Digital Health and Information Technology Market, 2019-2030

Figure 8.65: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2019-2030

Figure 8.66: Global Precision Medicine CDSS Market, 2019-2030

Figure 8.67: Big Data Attributes

Figure 8.68: Global Precision Medicine Big Data Analytics Market, 2019-2030

Figure 8.69: Big Data Analytics: Key Benefits

Figure 8.70: Global Precision Medicine IT Infrastructure Market, 2019-2030

Figure 8.71: Global Precision Medicine IT Infrastructure Market (by Type), 2019-2030

Figure 8.72: Global Precision Medicine Genomics Informatics Market, 2019-2030

Figure 8.73: Global Precision Medicine Genomics Informatics Market (by Product Type), 2019-2030

Figure 8.74: Global Precision Medicine In-Silico Informatics Market, 2019-2030

Figure 8.75: Global Precision Medicine Mobile Health Market, 2019-2030

Figure 8.76: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2019-2030

Figure 8.77: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2019-2030

Figure 8.78: Global Precision Medicine Therapeutics Market, 2019-2030

Figure 8.79: Global Precision Medicine Therapeutics Market (by Type), 2019-2030

Figure 8.80: Global Precision Medicine Clinical Trials Market, 2019-2030

Figure 8.81: Global Precision Medicine Clinical Trials Market (by Region), 2019-2030

Figure 8.82: Types of Cell Therapy

Figure 8.83: Global Precision Medicine Cell Therapy Market, 2019-2030

Figure 8.84: Global Precision Medicine Cell Therapy Market (by Region), 2019-2030

Figure 8.85: Global Precision Medicine Drug Discovery and Research Market, 2019-2030

Figure 8.86: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030

Figure 8.87: Types of Gene Therapy

Figure 8.88: Types of Gene Therapy

Figure 8.89: Global Precision Medicine Gene Therapy Market, 2019-2030

Figure 8.90: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030

Figure 9.1: Global Precision Medicine Applications Market, 2019-2030

Figure 9.2: Types of Cancer

Figure 9.3: Global Precision Medicine Oncology Market, 2019-2030

Figure 9.4: Global Precision Medicine Infectious Diseases Market, 2019-2030

- Figure 9.5: Number of Deaths by Top 18 Infectious Diseases, 2018
- Figure 9.6: Global Precision Medicine Neurology Market, 2019-2030
- Figure 9.7: Global Precision Medicine Cardiovascular Market, 2019-2030
- Figure 9.8: Global Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
- Figure 9.9: Global Precision Medicine Gastroenterology Market, 2019-2030
- Figure 9.10: Global Precision Medicine Other Applications Market, 2019-2030
- Figure 10.1: Global Precision Medicine Market (by Region), 2019 and 2030
- Figure 10.2: Global Precision Medicine Market (by Region), 2019-2030
- Figure 10.3: North America Precision Medicine Market, 2019-2030
- Figure 10.4: North America: Market Dynamics
- Figure 10.5: North America Precision Medicine Market (by Ecosystem), 2019-2030
- Figure 10.6: North America Precision Medicine Market (by Country), 2019-2030
- Figure 10.7: U.S. Precision Medicine Market, 2019-2030
- Figure 10.9: Europe Precision Medicine Market, 2019-2030
- Figure 10.10: Europe: Market Dynamics
- Figure 10.11: Europe Precision Medicine Market (by Ecosystem), 2019-2030
- Figure 10.12: Europe Precision Medicine Market (by Country), 2019-2030
- Figure 10.13: Germany Precision Medicine Market, 2019-2030
- Figure 10.14: France Precision Medicine Market, 2019-2030
- Figure 10.15: Italy Precision Medicine Market, 2019-2030
- Figure 10.16: The U.K. Precision Medicine Market, 2019-2030
- Figure 10.17: Spain Precision Medicine Market, 2019-2030
- Figure 10.18: Rest-of-Europe Precision Medicine Market, 2019-2030
- Figure 10.19: Asia-Pacific Precision Medicine Market, 2019-2030
- Figure 10.20: APAC: Market Dynamics
- Figure 10.21: Asia-Pacific Precision Medicine Market (by Ecosystem), 2019-2030
- Figure 10.22: Asia-Pacific Precision Medicine Market (by Country), 2019-2030
- Figure 10.23: China Precision Medicine Market, 2019-2030
- Figure 10.24: Japan Precision Medicine Market, 2019-2030
- Figure 10.25: Australia Precision Medicine Market, 2019-2030
- Figure 10.26: India Precision Medicine Market, 2019-2030
- Figure 10.27: Rest-of-Asia-Pacific Precision Medicine Market, 2019-2030
- Figure 10.28: Latin America Precision Medicine Market, 2019-2030
- Figure 10.29: APAC: Market Dynamics
- Figure 10.30: Latin America Precision Medicine Market (by Ecosystem), 2019-2030
- Figure 10.31: Latin America Precision Medicine Market (by Country), 2019-2030
- Figure 10.32: Brazil Precision Medicine Market, 2019-2030
- Figure 10.33: Mexico Precision Medicine Market, 2019-2030
- Figure 10.34: Rest-of-Latin America Precision Medicine Market, 2019-2030

- Figure 10.35: Rest-of-the-World Precision Medicine Market (by Ecosystem), 2019-2030
- Figure 10.36: Rest-of-the-World Precision Medicine Market, 2019-2030
- Figure 11.1: Total Number of Companies Profiled
- Figure 11.2: Abbott Laboratories: Product Portfolio
- Figure 11.3: Abbott Laboratories: Overall Financials, 2017-2019
- Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
- Figure 11.5: Abbott Laboratories: Revenue (by Region), 2017-2019
- Figure 11.6: Abbott Laboratories: R&D Expenditure, 2017-2019
- Figure 11.7: Abbott Laboratories: SWOT Analysis
- Figure 11.8: Almac Group Ltd.: SWOT Analysis
- Figure 11.9: Abbott Laboratories: Product Portfolio
- Figure 11.10: Amgen Inc.: Overall Financials, 2017-2019
- Figure 11.11: Amgen Inc.: Revenue (by Region), 2018-2019
- Figure 11.12: Amgen Inc. R&D Expenditure, 2017-2019
- Figure 11.13: Amgen Inc.: SWOT Analysis
- Figure 11.14: ANGLE plc: Overall Financials, 2017-2019
- Figure 11.15: ANGLE plc: Revenue (by Region), 2018-2019
- Figure 11.16: ANGLE plc R&D Expenditure, 2017-2019
- Figure 11.17: ANGLE plc: SWOT Analysis
- Figure 11.18: Astellas Pharma Inc.: Product Portfolio
- Figure 11.19: Astellas Pharma Inc.: Overall Financials, 2017-2019
- Figure 11.20: Astellas Pharma Inc. R&D Expenditure, 2017-2019
- Figure 11.21: Astellas Pharma Inc.: SWOT Analysis
- Figure 11.22: Astra Zeneca: Product Portfolio
- Figure 11.23: Astra Zeneca: Overall Financials, 2017-2019
- Figure 11.24: Astra Zeneca: Revenue (by Business Segment), 2017-2019
- Figure 11.25: Astra Zeneca: Revenue (by Region), 2017-2019
- Figure 11.26: Astra Zeneca: SWOT Analysis
- Figure 11.27: ASURAGEN INC.: SWOT Analysis
- Figure 11.28: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
- Figure 11.29: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
- Figure 11.30: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
- Figure 11.31: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
- Figure 11.32: Bio-Rad Laboratories, Inc: SWOT Analysis
- Figure 11.33: bioMérieux S.A.: Product Portfolio
- Figure 11.34: bioMérieux S.A.: Overall Financials, 2017-2019
- Figure 11.35: bioMérieux S.A.: Revenue (by Segment), 2017-2019
- Figure 11.36: bioMérieux S.A.: Revenue (by Region), 2018-2019
- Figure 11.37: bioMérieux S.A.: SWOT Analysis

- Figure 11.38: Bristol-Myers Squibb Company: Product Portfolio
- Figure 11.39: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
- Figure 11.40: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
- Figure 11.41: Bristol-Myers Squibb Company.: SWOT Analysis
- Figure 11.42: Cardiff Oncology.: Product Portfolio
- Figure 11.43: Cardiff Oncology: Overall Financials, 2018-2019
- Figure 11.44: Cardiff Oncology: R&D Expenditure, 2018-2019
- Figure 11.45: Cardiff Oncology: SWOT Analysis
- Figure 11.46: CETICS Healthcare Technologies GmbH: SWOT Analysis
- Figure 11.47: Danaher Corporation: Overall Financials, 2017-2019
- Figure 11.48: Danaher Corporation: Revenue (by Business Segment), 2017-2019
- Figure 11.49: Danaher Corporation: SWOT Analysis
- Figure 11.50: Eli Lilly and Company Limited: Product Portfolio
- Figure 11.51: Eli Lilly and Company Limited: Overall Financials, 2017-2019
- Figure 11.52: Eli Lilly and Company Limited: Revenue (by Region), 2018-2019
- Figure 11.53: Eli Lilly and Company Limited: SWOT Analysis
- Figure 11.54: Epic Sciences, Inc.: Product Portfolio
- Figure 11.55: Epic Sciences, Inc.: SWOT Analysis
- Figure 11.56: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 11.57: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
- Figure 11.58: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
- Figure 11.59: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
- Figure 11.60: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
- Figure 11.61: F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 11.62: GE Healthcare: Product Portfolio
- Figure 11.63: General Electric Company: Overall Financials, 2017-2019
- Figure 11.64: General Electric Company: Revenue Split for Healthcare, 2017-2019
- Figure 11.65: General Electric: Healthcare Revenue (by Region), 2017-2019
- Figure 11.66: General Electric Company: R&D Expenditure, 2017-2019
- Figure 11.67: General Electric Company: SWOT Analysis
- Figure 11.68: Gilead Sciences, Inc.: Product Portfolio
- Figure 11.69: Gilead Science, Inc.: SWOT Analysis
- Figure 11.70: GlaxoSmithKline plc: Overall Financials, 2017-2019
- Figure 11.71: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
- Figure 11.72: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
- Figure 11.73: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
- Figure 11.74: GlaxoSmithKline plc: SWOT Analysis
- Figure 11.75: Illumina, Inc.: Product Portfolio
- Figure 11.76: Illumina, Inc.: Overall Financials, 2017-2019

- Figure 11.77: Illumina, Inc.: Revenue (by Segment), 2017-2019
- Figure 11.78: Illumina, Inc.: Revenue (by Region), 2017-2019
- Figure 11.79: Illumina, Inc.: R&D Expenditure, 2017-2019
- Figure 11.80: Illumina, Inc.: SWOT Analysis
- Figure 11.81: Intomics A/S: SWOT Analysis
- Figure 11.82: Illumina, Inc.: Product Portfolio
- Figure 11.83: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
- Figure 11.84: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
- Figure 11.85: Johnson & Johnson Services, Inc.: SWOT Analysis
- Figure 11.86: Konica Minolta, Inc.: Overall Financials, 2017-2019
- Figure 11.87: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
- Figure 11.88: Konica Minolta, Inc.: SWOT Analysis
- Figure 11.89: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
- Figure 11.90: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
- Figure 11.91: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
- Figure 11.92: Laboratory Corporation of America Holdings: SWOT Analysis
- Figure 11.93: MDx Health, Inc.: Overall Financials, 2017--2019
- Figure 11.94: MDx Health, Inc.: SWOT Analysis
- Figure 11.95: Menarini Silicon Biosystems, Inc.: SWOT Analysis
- Figure 11.96: Merck KGaA: Product Portfolio
- Figure 11.97: Merck KGaA: Overall Financials, 2017-2019
- Figure 11.98: Merck KGaA: Revenue (by Segment), 2017-2019
- Figure 11.99: Merck KGaA: Revenue (by Region), 2017-2019
- Figure 11.100: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019
- Figure 11.101: Merck KGaA: R&D Expenditure, 2017-2019
- Figure 11.102: Merck KGaA: SWOT Analysis
- Figure 11.103: Myriad Genetics, Inc.: Product Portfolio
- Figure 11.104: Myriad Genetics, Inc.: Overall Financials, 2017-2019
- Figure 11.105: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
- Figure 11.106: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
- Figure 11.107: Myriad Genetics, Inc.: SWOT Analysis
- Figure 11.108: Novartis AG: Overall Product Portfolio
- Figure 11.109: Novartis AG: Overall Financials, 2017-2019
- Figure 11.110: Novartis AG Net Revenue (by Business Segment), 2017-2019
- Figure 11.111: Novartis AG: Net Revenue (by Region), 2017-2019

Figure 11.112: Novartis AG: R& D Expense, 2017-2019

Figure 11.113: Novartis AG: SWOT Analysis

Figure 11.114: Oracle Corporation: Overall Financials, 2017-2019

Figure 11.115: Oracle Corporation: Revenue (by Region), 2017-2019

Figure 11.116: Oracle Corporation R&D Expenditure, 2017-2019

Figure 11.118: Pacific Biosciences of California, Inc.: Overall Product Portfolio

Figure 11.119: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019

Figure 11.120: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019

Figure 11.121: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019

Figure 11.122: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019

Figure 11.123: Pacific Biosciences of California, Inc.: SWOT Analysis

Figure 11.124: Partek, Inc.: SWOT Analysis

Figure 11.125: Pfizer Inc.: Overall Product Portfolio

Figure 11.126: Pfizer Inc.: Overall Financials, 2017-2019

Figure 11.127: Pfizer Inc.: Revenue (by Segment), 2017-2019

Figure 11.128: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019

Figure 11.129: Pfizer Inc.: Revenue (by Region), 2017-2019

Figure 11.130: Pfizer Inc: R&D Expenditure, 2017-2019

Figure 11.131: Pfizer Inc.: SWOT Analysis

Figure 11.132: QIAGEN N.V.: Portfolio

Figure 11.133: QIAGEN N.V.: Overall Financials, 2017-2019

Figure 11.134: QIAGEN N.V.: Revenue (by Segment), 2017-2019

Figure 11.135: QIAGEN N.V.: Revenue (by Region), 2017-2019

Figure 11.136: QIAGEN N.V.: R&D Expenditure, 2017-2019

Figure 11.137: QIAGEN N.V.: SWOT Analysis

Figure 11.138: Quest Diagnostics Incorporated: Overall Financials, 2017-2019

Figure 11.139: Quest Diagnostics Incorporated: SWOT Analysis

Figure 11.140: Randox Laboratories Ltd.: SWOT Analysis

Figure 11.141: Sanofi SA: Product Portfolio

Figure 11.142: Sanofi SA: Overall Financials, 2017-2019

Figure 11.143: Sanofi SA: Revenue (by Segment), 2017-2019

Figure 11.144: Sanofi SA: Revenue (by Region), 2017-2019

Figure 11.145: Sanofi SA: R&D Expenditure, 2017-2019

Figure 11.146: Sanofi SA: SWOT Analysis

Figure 11.147: Sysmex Corporation: Overall Financials, 2017-2019

Figure 11.148: Sysmex Corporation: Revenue (by Business Segment), 2018-2019

Figure 11.149: Sysmex Corporation R&D Expenditure, 2017-2019

Figure 11.150: Sysmex Corporation: SWOT Analysis

- Figure 11.151: Teva Pharmaceuticals Industries Ltd.: Product Portfolio
- Figure 11.152: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
- Figure 11.153: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
- Figure 11.154: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
- Figure 11.155: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
- Figure 11.156: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 11.157: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
- Figure 11.158: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
- Figure 11.159: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
- Figure 11.160: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
- Figure 11.161: Thermo Fisher Scientific Inc.: SWOT Analysis

## I would like to order

Product name: Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Product link: <https://marketpublishers.com/r/G560D23BF894EN.html>

Price: US\$ 7,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G560D23BF894EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970